ABEO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
13.5M
+18.6%
11.4M
+30.5%
8.7M
+60.9%
5.4M
0
Cost of Revenue
5.7M
+36.8%
4.2M
+54.9%
2.7M
+158.2%
1.0M
+113.9%
488.0K
Gross Profit
7.8M
+8.0%
7.2M
+19.6%
6.0M
+37.7%
4.4M
+996.7%
-488000
Operating Expenses
20.8M
-0.4%
20.9M
-28.2%
29.1M
+6.5%
27.3M
+16.0%
23.5M
R&D
3.7M
-26.9%
5.0M
-47.5%
9.6M
+42.4%
6.7M
+59.2%
4.2M
SG&A
17.1M
+8.0%
15.8M
-18.8%
19.5M
+3.8%
18.8M
-2.8%
19.3M
Operating Income
-13001000
+4.8%
-13653000
+40.7%
-23033000
-0.5%
-22911000
+4.6%
-24018000
EBITDA
-12296000
+5.3%
-12988000
+41.9%
-22343000
-1.3%
-22048000
+5.8%
-23410000
Net Income
-4808000
+76.2%
-20191000
-18.2%
-17075000
+16.5%
-20460000
-296.4%
-5161000
EPS (Basic)
$-0.08
+77.1%
$-0.35
-16.7%
$-0.30
+18.9%
$-0.37
-270.0%
$-0.10
EPS (Diluted)
$-0.08
+77.1%
$-0.35
-16.7%
$-0.30
-36.4%
$-0.22
-120.0%
$-0.10
Shares (Diluted)
57.9M
+1.4%
57.0M
+0.8%
56.6M
-39.7%
93.9M
+73.1%
54.2M
Abeona Therapeutics (ABEO) — Financials